148 related articles for article (PubMed ID: 31378656)
1. Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
Abdel-Rahman O
Clin Colorectal Cancer; 2019 Dec; 18(4):e385-e393. PubMed ID: 31378656
[TBL] [Abstract][Full Text] [Related]
2. Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Abdel-Rahman O
Clin Colorectal Cancer; 2019 Jun; 18(2):110-115.e2. PubMed ID: 30679026
[TBL] [Abstract][Full Text] [Related]
3. Impact of age on toxicity and efficacy of 5-FU-based combination chemotherapy among patients with metastatic colorectal cancer; a pooled analysis of five randomized trials.
Abdel-Rahman O; Karachiwala H
Int J Colorectal Dis; 2019 Oct; 34(10):1741-1747. PubMed ID: 31492988
[TBL] [Abstract][Full Text] [Related]
4. ECOG performance score 0 versus 1: impact on efficacy and safety of first-line 5-FU-based chemotherapy among patients with metastatic colorectal cancer included in five randomized trials.
Abdel-Rahman O
Int J Colorectal Dis; 2019 Dec; 34(12):2143-2150. PubMed ID: 31732876
[TBL] [Abstract][Full Text] [Related]
5. 5-Fluorouracil-related Cardiotoxicity; Findings From Five Randomized Studies of 5-Fluorouracil-based Regimens in Metastatic Colorectal Cancer.
Abdel-Rahman O
Clin Colorectal Cancer; 2019 Mar; 18(1):58-63. PubMed ID: 30470591
[TBL] [Abstract][Full Text] [Related]
6. Panitumumab-based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: A retrospective analysis of two randomised trials.
Modest DP; Rivera F; Bachet JB; de Braud F; Pietrantonio F; Koukakis R; Demonty G; Douillard JY
Int J Cancer; 2019 Jul; 145(2):576-585. PubMed ID: 30614531
[TBL] [Abstract][Full Text] [Related]
7. A meta-analysis of chemotherapy regimen fluorouracil/leucovorin/oxaliplatin compared with fluorouracil/leucovorin in treating advanced colorectal cancer.
Chen ML; Fang CH; Liang LS; Dai LH; Wang XK
Surg Oncol; 2010 Mar; 19(1):38-45. PubMed ID: 19345093
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of FOLFIRI Regimen in Elderly Versus Nonelderly Patients with Metastatic Colorectal or Gastric Cancer.
Kim JW; Lee KW; Kim KP; Lee JH; Hong YS; Kim JE; Kim SY; Park SR; Nam BH; Cho SH; Chung IJ; Park YS; Oh HS; Lee MA; Kang HJ; Park YI; Song EK; Han HS; Lee KT; Shin DB; Kang JH; Zang DY; Kim JH; Kim TW
Oncologist; 2017 Mar; 22(3):293-303. PubMed ID: 28209749
[TBL] [Abstract][Full Text] [Related]
9. SAPPHIRE: a randomised phase II study of planned discontinuation or continuous treatment of oxaliplatin after six cycles of modified FOLFOX6 plus panitumumab in patients with colorectal cancer.
Munemoto Y; Nakamura M; Takahashi M; Kotaka M; Kuroda H; Kato T; Minagawa N; Noura S; Fukunaga M; Kuramochi H; Touyama T; Takahashi T; Miwa K; Satake H; Kurosawa S; Miura T; Mishima H; Sakamoto J; Oba K; Nagata N
Eur J Cancer; 2019 Sep; 119():158-167. PubMed ID: 31445198
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Value of Baseline ALBI Score Among Patients With Colorectal Liver Metastases: A Pooled Analysis of Two Randomized Trials.
Abdel-Rahman O
Clin Colorectal Cancer; 2019 Mar; 18(1):e61-e68. PubMed ID: 30348618
[TBL] [Abstract][Full Text] [Related]
11. Impact of diabetes comorbidity on the efficacy and safety of FOLFOX first-line chemotherapy among patients with metastatic colorectal cancer: a pooled analysis of two phase-III studies.
Abdel-Rahman O
Clin Transl Oncol; 2019 Apr; 21(4):512-518. PubMed ID: 30182209
[TBL] [Abstract][Full Text] [Related]
12. Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study.
Folprecht G; Pericay C; Saunders MP; Thomas A; Lopez Lopez R; Roh JK; Chistyakov V; Höhler T; Kim JS; Hofheinz RD; Ackland SP; Swinson D; Kopp M; Udovitsa D; Hall M; Iveson T; Vogel A; Zalcberg JR
Ann Oncol; 2016 Jul; 27(7):1273-9. PubMed ID: 27091810
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials.
Arkenau HT; Arnold D; Cassidy J; Diaz-Rubio E; Douillard JY; Hochster H; Martoni A; Grothey A; Hinke A; Schmiegel W; Schmoll HJ; Porschen R
J Clin Oncol; 2008 Dec; 26(36):5910-7. PubMed ID: 19018087
[TBL] [Abstract][Full Text] [Related]
14. A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES).
Pinter T; Klippel Z; Cesas A; Croitoru A; Decaestecker J; Gibbs P; Hotko Y; Jassem J; Kurteva G; Novotny J; O'Reilly S; Salek T; Reiner M; Morrow PK; Choi MR; Whittaker S; Blanke C
Clin Colorectal Cancer; 2017 Jun; 16(2):103-114.e3. PubMed ID: 28038865
[TBL] [Abstract][Full Text] [Related]
15. Safety and Efficacy of a Modified FLOX Adjuvant Regimen for Patients With Stage III Colorectal Cancer Treated in the Community.
Protásio BM; Matutino A; Lage LV; Santana I; Ramos R; Sabbaga J; Capareli F; Saragiotto D; Riechelmann R; Hoff PM
Clin Colorectal Cancer; 2017 Mar; 16(1):65-72. PubMed ID: 27515842
[TBL] [Abstract][Full Text] [Related]
16. A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy.
Hecht JR; Pillai M; Gollard R; Heim W; Swan F; Patel R; Dreiling L; Mo M; Malik I
Clin Colorectal Cancer; 2010 Apr; 9(2):95-101. PubMed ID: 20378503
[TBL] [Abstract][Full Text] [Related]
17. Sex-dependent least toxic timing of irinotecan combined with chronomodulated chemotherapy for metastatic colorectal cancer: Randomized multicenter EORTC 05011 trial.
Innominato PF; Ballesta A; Huang Q; Focan C; Chollet P; Karaboué A; Giacchetti S; Bouchahda M; Adam R; Garufi C; Lévi FA
Cancer Med; 2020 Jun; 9(12):4148-4159. PubMed ID: 32319740
[TBL] [Abstract][Full Text] [Related]
18. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen.
André T; Bensmaine MA; Louvet C; François E; Lucas V; Desseigne F; Beerblock K; Bouché O; Carola E; Merrouche Y; Morvan F; Dupont-André G; de Gramont A
J Clin Oncol; 1999 Nov; 17(11):3560-8. PubMed ID: 10550155
[TBL] [Abstract][Full Text] [Related]
19. Oral uracil-tegafur plus leucovorin vs fluorouracil bolus plus leucovorin for advanced colorectal cancer: a meta-analysis of five randomized controlled trials.
Bin Q; Li J; Liao C; Cao Y; Gao F
Colorectal Dis; 2011 Aug; 13(8):837-45. PubMed ID: 20050863
[TBL] [Abstract][Full Text] [Related]
20. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
